Two former Stanford researchers nab a $41M launch round to learn the secrets of the ‘secretome’
A new startup on the West Coast wants to tackle chronic diseases and age-related conditions, and it’s trying to do so using the world of “secreted proteins.”
Juvena Therapeutics emerged with a $41 million Series A on Monday morning, nabbing Mubadala Capital — the UAE’s sovereign wealth fund — and Horizons Ventures as its lead investors. A platform play, the biotech intends to use the funds primarily to build out its map of the “secretome” while also advancing a handful of discovery-stage experimental drugs.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.